MaxCyte, Inc.
("MaxCyte" or the "Company")
TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN
Total Voting Rights
Date: 3 October 2022: MaxCyte (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, it has recently issued 47,429 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options. The new Common Stock will rank pari passu with the existing shares of common stock of the Company.
As of 30 September 2022, the total issued stock capital of the Company following the recent issue of the new Common Stock is 101,904,313 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.
Block Listing Return
MaxCyte also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:
|
Name of applicant:
|
MaxCyte, Inc.
|
|
Name of scheme:
|
MaxCyte Long Term Incentive Plan
|
|
Period of return:
|
From:
|
1 March 2022
|
To:
|
30 September 2022
|
|
Balance of unallotted securities under scheme(s) from previous return:
|
12,177,084 ordinary shares of common stock at $0.01 each
|
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
|
Nil
|
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
|
647,481 ordinary shares of common stock at $0.01 each
|
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
|
11,529,603 ordinary shares of common stock at $0.01 each
|
|
|
|
|
|
|
Name of contact:
|
Ron Holtz, Chief Financial Officer
|
|
Telephone number of contact:
|
+1 301 944 1624
|
|
|
For further information, please contact:
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
|
|
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
|
|
|
|
|
|
|
|
|
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation®platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
